Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies. An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy

JACC: Cardiovascular Interventions

Volumn 2, Issue 8, 2009, Pages 748-757

  Mehran, Roxana ^a   Nikolsky, Eugenia ^a   Lansky, Alexandra J ^a   Kirtane, Ajay J ^a   Kim, Young Hak ^a   Feit, Frederick ^b   Manoukian, Steven ^c   Moses, Jeffrey W ^a   Ebrahimi, Ramin ^d   Ohman, E Magnus ^e   White, Harvey D ^f   Pocock, Stuart J ^g   Dangas, George D ^a   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

acute coronary syndromes; anticoagulants; bivalirudin; chronic kidney disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CHRONIC DISEASE; CORONARY ARTERY BYPASS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; ODDS RATIO; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TRIAGE;

EID: 68949176893     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.05.018     Document Type: Article

References (32)

1. Januzzi Jr. J.L., Snapinn S.M., DiBattiste P.M., Jang I.K., and Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 105 (2002) 2361-2366
2. Best P.J.M., Lennon R., Ting H.H., et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39 (2002) 1113-1119
3. Bhatt D.L., Chew D.P., Lincoff A.M., et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 92 (2003) 919-923
4. Berger P.B., Best P.J., Topol E.J., et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 149 (2005) 869-875
5. Gupta R., Birnbaum Y., and Uretsky B.F. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 44 (2004) 1343-1353
6. Lemos P.A., Arampatzis C.A., Saia F., et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 95 (2005) 167-172
7. Blackman D.J., Pinto R., Ross J.R., et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 151 (2006) 146-152
8. Hillis G.S., Croal B.L., Buchan K.G., et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 113 (2006) 1056-1062
9. Han J.H., Chandra A., Mulgund J., et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 119 (2006) 248-254
10. Chew D.P., Lincoff A.M., Gurm H., et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95 (2005) 581-585
11. Grand'Maison A., Charest A.F., and Geerts W.H. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 5 (2005) 291-305
12. Reed M.D., and Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 22 (2002) 105S-111S
13. Sagripanti A., Cozza V., Baicchi U., Camici M., Cupisti A., and Barsotti G. Increased thrombin generation in patients with chronic renal failure. Int J Clin Lab Res 27 (1997) 72-75
14. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
15. Stone G.W., Ware J.H., Bertrand M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY trial. JAMA 298 (2007) 2497-2506
16. Stone G.W., Bertrand M., Colombo A., et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148 (2004) 764-775
17. Stone G.W., Bertrand M.E., Moses J.W., et al., ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297 (2007) 591-602
18. Sadeghi H.M., Stone G.W., Grines C.L., et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108 (2003) 2769-2775
19. Cooper W.A., O'Brien S.M., Thourani V.H., et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 113 (2006) 1063-1070
20. Panichi V., Migliori M., De Pietro S., et al. C reactive protein in patients with chronic renal diseases. Ren Fail 23 (2001) 551-562
21. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
22. Schwarz U., Buzello M., Ritz E., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 (2000) 218-223
23. Goldsmith D.J., and Covic A. Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int 60 (2001) 2059-2078
24. Jeremias A., Bhatt D.L., Chew D.P., et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 89 (2002) 1209-1211
25. Reddan D.N., O'Shea J.C., Sarembock I.J., et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). Am J Cardiol 91 (2003) 17-21
26. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-882
27. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
28. Mehran R., Pocock S.J., Stone G.W., et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30 (2009) 1457-1466
29. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
30. Kirtane A.J., Piazza G., Murphy S.A., et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47 (2006) 2374-2379
31. LaPointe N.M., Chen A.Y., Alexander K.P., et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non-ST-segment elevation acute coronary syndromes. Arch Intern Med 167 (2007) 1539-1544
32. Hernandez A.V., Boersma E., Murray G.D., Habbema J.D.F., and Steyerberg E.W. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?. Am Heart J 151 (2006) 257-264